Health-related quality of life in people with type 2 diabetes participating in the LEADER trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

To assess health-related quality of life (HRQoL) in people with type 2 diabetes (T2D) participating in the LEADER cardiovascular outcomes trial using the five-dimension European Quality of Life questionnaire (EQ-5D).

Who Took Part

According to the abstract, 36 participants were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States.

The researchers compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Liraglutide, giving a reference point.

The researchers also assessed which complications had the greatest impact on quality of life.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Health Status, Liraglutide, Patient Reported Outcome Measures, Quality of Life, Self Care and Surveys and Questionnaires.

The authors tagged it with the keywords EQ-5D, LEADER, health-related quality of life, patient-reported outcomes and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 36 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page.